Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma – Cheeky Pint

Market views

Bullish

LLY— Eli Lilly's market cap premium is driven by GLP-1 success and superior R&D productivity. The company maintains 20-25% R&D spending on growing revenues, creating a sustainable innovation engine. Their pricing model funds future innovation with a quarter of every dollar going to research.
DTC— Direct-to-consumer pharmaceutical platforms are disrupting traditional distribution. Lilly Direct has become the largest online prescription platform by revenue, annualizing in the billions of dollars.
ORALGPL1— Oral GLP-1 formulations are critical for scaling beyond injectable capacity constraints to reach hundreds of millions of users. They must be approved to meet massive market demand.
INFLAM— GLP-1 drugs show promise beyond weight loss with anti-inflammatory effects. Clinical trials are combining GLP-1s with inflammatory disease treatments like psoriasis drugs.
BIOTECH— Biotechnology sector has potential for creating mega-markets through transformative therapies like Alzheimer's prevention, enabled by success in other areas like GLP-1s.
CHINABIO— Chinese biotech has dramatically increased its share of the global drug pipeline from single digits to nearly a third over the past decade.
NVDA— NVIDIA is becoming essential infrastructure for pharmaceutical R&D. Eli Lilly is building an on-premise supercomputer with NVIDIA's latest B300 chipset for drug discovery.

Bearish

COMPOUND— Compounding pharmacies face significant risks from IP theft violations and safety concerns, with reports of chronic kidney failure and permanent liver damage from their products.
FOOD— Food companies face structural headwinds as GLP-1 drugs reduce caloric intake by 800 calories per day without causing hunger, directly threatening food industry volumes.
PBMS— Pharmacy Benefit Managers built rent-seeking models on outdated technology that can now be easily disintermediated through direct-to-consumer channels.
GENERICS— Generic drug manufacturing has completely moved offshore in pursuit of low costs, with no generics manufactured in the US, creating supply chain vulnerabilities.

Not investment advice.